TB-500 vs KPV
§ 01 — Attributes
Summary
A synthetic fragment of the naturally occurring protein thymosin beta-4, used in research for its effects on cell migration, angiogenesis, and tissue repair following injury.
A short three-amino-acid peptide derived from α-MSH. Potent anti-inflammatory, most used for gut inflammation, mast cell activation, and autoimmune flares.
Mechanism
TB-500 binds to G-actin, regulating actin polymerisation and promoting cell migration to injured tissue. It upregulates VEGF-driven angiogenesis and modulates inflammatory cytokine profiles.
KPV inhibits NF-κB signalling and reduces pro-inflammatory cytokine production (TNF-α, IL-6). Unlike systemic immunosuppressants, it modulates inflammation without broad immunosuppression.
Typical dose
2–10 mg per week (research protocols)
500 mcg – 1 mg daily (oral or subcutaneous)
Half-life
~2–3 days
Not well characterised
Administration
Subcutaneous, Intramuscular
Oral, Subcutaneous
Regulatory status
research-only
research-only
Cheapest in stock
£30 · £6.0/mg via Peptides UK
£80 · £5.3/mg via My-Peptides
Offers tracked
3
1